Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

disease progression

Streamlining Healthcare Delivery Through Digital Care Journeys

Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,...

Impetus Digital

EU flag

European Commission grants AstraZeneca three new approvals

The indications are for adults with liver and lung cancers, and chronic lymphocytic leukaemia

EU flag

EC approves first gene therapy for adults with haemophilia B

Typically, haemophilia B patients must adhere to strict, lifelong IV infusion schedules

EU flag

EC approves UCB’s Fintepla to treat severe form of epilepsy

Lennox-Gastaut syndrome affects around two in 10,000 people in the EU and usually begins in early childhood

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis

This makes Dupixent the first and only targeted medicine indicated for this condition

- PMLiVE

Sandoz’s high concentration Hyrimoz formulation recommended for use in EU

The recommendation includes multiple indications such as rheumatoid arthritis and Crohn’s disease

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

- PMLiVE

EC launches cancer imaging initiative to accelerate innovation and early diagnosis

Researchers will have better access to high-quality resources and databases

- PMLiVE

Roche’s influenza medicine approved by EC for children

Xofluza is now the first single-dose, oral influenza medicine approved in Europe for children

- PMLiVE

Merck KGaA and Mersana partner in potential $830m deal

The companies will work together to develop novel antibody-drug conjugates

- PMLiVE

EC approves Atara and Pierre Fabre’s Ebvallo as monotherapy for Epstein-Barr patients

The approval is for adults and those over two years old with relapsed or refractory EBV+PTLD

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links